Drug intelligence / Profile preview

TERAH-7

Development stage: Preclinical
Lead developer: ImunoTera
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

TERAH-7 is a therapeutic vaccine based on a recombinant protein developed by the Brazilian startup ImunoTera. It is designed to treat diseases caused by the Human Papillomavirus (HPV), including cervical cancer, oropharyngeal cancer, anal cancer, and carcinoma in situ. The vaccine is built on the 'Act-Tera' technology platform, which is engineered to activate the immune system, specifically generating T cells that target and eliminate HPV-infected cells. Preclinical data suggests that TERAH-7 can induce tumor regression, prevent metastasis and recurrence, and work synergistically with standard chemotherapy treatments. Early patient studies have also indicated the potential for lesion regression in cervical neoplasms.

Targets

HPV (Human papillomavirus)

Beyond the preview

Go deeper on TERAH-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TERAH-7.

Explore the full profile